Filing Flows › Dogwood Therapeutics (DWTX) › Guidance & outlook
Dogwood Therapeutics (DWTX) guidance and outlook
Dogwood Therapeutics' 10-Q filed Nov 6, 2026 makes 4 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 6, 2026
- We will be providing our clinical development expertise, but with the NCI funding the trial, we will incur no further expenses in connection with this initial evaluation of the safety of SP16 in cancer patients.
- To date, we have not generated any revenue from the sale of products and we do not anticipate generating any revenue from the sales of products for the foreseeable future.
- We anticipate our cash on hand at September 30, 2026 of approximately $4.9 million plus the cash received from the October 2026 Offering of $5 million will fund operations through the first quarter of 2027.
- We will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives.
Dogwood Therapeutics' latest quarter
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
What does Dogwood Therapeutics expect?
We will be providing our clinical development expertise, but with the NCI funding the trial, we will incur no further expenses in connection with this initial evaluation of the safety of SP16 in cancer patients. To date, we have not generated any revenue from the sale of products and we do not anticipate generating any revenue from the sales of products for the foreseeable future. We anticipate our cash on hand at September 30, 2026 of approximately $4.9 million plus the cash received from the October 2026 Offering of $5 million will fund operations through the first quarter of 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.